Waypoint Bio

Waypoint Bio is an early-stage biotech developing AI-driven cell therapies for solid tumors, a major challenge in oncology. Its core innovation is a spatial pooled screening platform that tests thousands of cell therapy designs in a single in vivo experiment, using machine learning to rank and iteratively optimize candidates. The company has two disclosed CAR-T programs in discovery and lead optimization stages, targeting CLDN18.2 and an undisclosed antigen for gastric and lung/prostate cancers, respectively. Backed by a team with deep expertise in spatial biology, AI, and genomics, Waypoint aims to compress years of R&D into accelerated, data-rich development cycles.

AI-powered platform integrating spatial pooled screening (in vivo testing of thousands of therapy designs in parallel), computer vision for multi-plex spatial phenotyping, and generative AI/machine learning for design optimization and ranking.

Waypoint competes with other biotechs developing solid tumor cell therapies (e.g., with TCRs, armored CARs) and with a growing number of AI/ML-driven drug discovery platforms. Its unique differentiator is the integration of high-throughput *in vivo* spatial pooled screening with generative AI, a combination not widely deployed. It must compete for talent, data, and capital with larger, well-funded entities in both spheres.